IRIS – Institutional Research Information System
IRIS è il sistema di gestione della ricerca dell’Università degli Studi di Milano-Bicocca.Il repository BOA è il modulo del sistema dedicato alla raccolta e alla disseminazione della produzione scientifica di Ateneo. Le pubblicazioni sono ricercabili per parola chiave attraverso il box nella barra orizzontale in alto oppure, mediante il pulsante Sfoglia, per "Afferenza", "Autore", "Titolo", "Tipologia" o "Settore scientifico-disciplinare".
IRIS contiene inoltre alcuni moduli dedicati alla registrazione dei progetti e dei contratti, e alla reportistica avanzata per le attività di valutazione della ricerca
EnglishIntroduction: As most patients with ovarian cancer experience multiple remissions and relapses, oncologists must prepare ahead for long-term treatment. While platinum-based regimens are standard of care for platinum-sensitive recurrence, there are circumstances in which platinum rechallenge is not the best approach. These situations include patients with limited sensitivity to platinum; patients with residual toxicity from previous platinum therapy; and patients at risk of developing hypersensitivity reactions. An alternative regimen for these patients is the non-platinum combination of trabectedin + pegylated liposomal doxorubicin (PLD). Areas covered: In this review, case studies are presented to illustrate how careful strategic planning, in terms of therapeutic choices and optimal sequencing, can achieve good outcomes in difficult-to-treat patients. Expert commentary: Advantages with use of trabectedin + PLD in selected patients with platinum-sensitive recurrent ovarian cancer include additional time to recover from platinum-related toxicities, avoidance of hypersensitivity reactions, and the ‘sequence effect’ by which trabectedin may enhance response to next platinum and prolong survival.
Colombo, N., Hardy-Bessard, A., Ferrandina, G., Marth, C., & Romero, I. (2016). Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge. EXPERT REVIEW OF ANTICANCER THERAPY, 16(sup1), 11-19 [10.1080/14737140.2016.1243475].
| Citazione: | Colombo, N., Hardy-Bessard, A., Ferrandina, G., Marth, C., & Romero, I. (2016). Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge. EXPERT REVIEW OF ANTICANCER THERAPY, 16(sup1), 11-19 [10.1080/14737140.2016.1243475]. | |
| Tipo: | Articolo in rivista - Articolo scientifico | |
| Carattere della pubblicazione: | Scientifica | |
| Presenza di un coautore afferente ad Istituzioni straniere: | Si | |
| Titolo: | Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge | |
| Autori: | Colombo, N; Hardy-Bessard, A; Ferrandina, G; Marth, C; Romero, I | |
| Autori: | ||
| Data di pubblicazione: | 2016 | |
| Lingua: | English | |
| Rivista: | EXPERT REVIEW OF ANTICANCER THERAPY | |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1080/14737140.2016.1243475 | |
| Appare nelle tipologie: | 01 - Articolo su rivista |
File in questo prodotto:
Copyright © 2021